Search alternatives:
significant models » significant degs (Expand Search), significant burdens (Expand Search), significant genes (Expand Search)
models based » model based (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant models » significant degs (Expand Search), significant burdens (Expand Search), significant genes (Expand Search)
models based » model based (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
Image_1_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.pdf
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
169
Image_2_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.pdf
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
170
Table_2_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
171
Table_3_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
172
Table_1_The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.docx
Published 2022“…Analogously, there was a significant decrease for dichotomous TTS (within vs over 5 weeks) in OS (P = .03) and progression free survival (PFS) (P = .01) but not for dichotomous TAC (within vs over 6 weeks) in OS and PFS (P = .40). …”
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180